Kazia Therapeutics

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

movers image

ABLV

ADVB

ATCH

CKPT

EXOD

HOOD

ICON

KZIA

LUNR

MLYS

NPWR

PSTV

SNOA

STBX

STSS

SUNE

TRVI

VEEE

Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket

Biotech

News

Health Care

Movers

Trading Ideas

General

Kazia Therapeutics updates paxalisib&#39;s regulatory progress after FDA discussions on glioblastoma data, highlighting plans for a pivotal Phase 3 trial.

Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?

Image49

Intraday Update

Markets

AEON

AGRI

AMIX

AREB

ASLN

ASTL

COIN

DATS

EAST

FSLR

FUFU

HUMA

INOD

LCFY

LCID

LXEO

MIRA

MLEC

MSTR

NAAS

NOVA

PETZ

POWW

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SCNI

SEDG

SQNS

TSLA

UPST

VTAK

Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics Ltd

Press Releases

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

Small Cap

Opinion

Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Offerings

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

Peraso Inc. (NASDAQ: PRSO): The Only Pure-Play mmWave Stock Poised for Growth – More Stocks Inside

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease

ATHE

ATOS

BNZI

HOLX

ONCY

PNPNF

PRSO

TSX:ONC

TSXV:PNPN

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Alzamend Neuro

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Azitra

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Ensysce Biosciences

Galecto

GT Biopharma

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

NuCana

Oragenics

Organovo Holdings

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Sunshine Biopharma

SILO Pharma

Soligenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Xenetic Biosciences

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

Maxim Group

HC Wainwright & Co.

Comments

Kazia Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga